- Home
- SNN vs NBIX Comparison
SNN vs NBIX Comparison
Compare SNN & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- NBIX
- Stock Information
- Founded
- SNN 1856
- NBIX 1992
- Country
- SNN United Kingdom
- NBIX United States
- Employees
- SNN N/A
- NBIX N/A
- Industry
- SNN Industrial Specialties
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNN Health Care
- NBIX Health Care
- Exchange
- SNN Nasdaq
- NBIX Nasdaq
- Market Cap
- SNN 12.7B
- NBIX 12.2B
- IPO Year
- SNN 1999
- NBIX 1996
- Fundamental
- Price
- SNN $28.83
- NBIX $126.55
- Analyst Decision
- SNN Hold
- NBIX Strong Buy
- Analyst Count
- SNN 3
- NBIX 20
- Target Price
- SNN $27.50
- NBIX $163.20
- AVG Volume (30 Days)
- SNN 801.1K
- NBIX 971.0K
- Earning Date
- SNN 07-31-2025
- NBIX 07-31-2025
- Dividend Yield
- SNN 2.60%
- NBIX N/A
- EPS Growth
- SNN 56.15
- NBIX N/A
- EPS
- SNN 0.47
- NBIX 2.96
- Revenue
- SNN $5,810,000,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- SNN $6.87
- NBIX $16.29
- Revenue Next Year
- SNN $5.19
- NBIX $15.08
- P/E Ratio
- SNN $30.88
- NBIX $42.79
- Revenue Growth
- SNN 4.70
- NBIX 21.73
- 52 Week Low
- SNN $23.69
- NBIX $84.23
- 52 Week High
- SNN $31.72
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- SNN 49.61
- NBIX 64.01
- Support Level
- SNN $28.40
- NBIX $122.66
- Resistance Level
- SNN $30.38
- NBIX $126.00
- Average True Range (ATR)
- SNN 0.36
- NBIX 2.55
- MACD
- SNN -0.17
- NBIX -0.33
- Stochastic Oscillator
- SNN 30.00
- NBIX 72.06
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.